Global safety of vaccines: Strengthening systems for monitoring, management and the role of GACVS

Expert Review of Vaccines

Volumn 8, Issue 6, 2009, Pages 705-716

  Zuber, Patrick L F ^a   Autran, Brigitte ^b   Asturias, Edwin J ^c   Evans, Stephen ^d   Hartigan Go, Kenneth ^e   Hussey, Gregory ^f   John, T Jacob ^g   Lambert, Paul Henri ^h   Law, Barbara ⁱ   Midthun, Karen ^j   Nohynek, Hanna ^k   Salmaso, Stefania ^l   Smith, Peter G ^d   Bentsi Enchill, Adwoa ^a   Caric, Aleksandra ^a   Pfeifer, Dina ^a   Duclos, Philippe ^a   Wood, David ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e Zuellig Foundation   (Philippines)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g CHRISTIAN MEDICAL COLLEGE   (India)

^h UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

ⁱ PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^j CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^k NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^l ISTITUTO SUPERIORE DI SANITÀ   (Italy)

more..

Author keywords

Adverse event; Immunization program; Monitoring signal; Pharmacovigilance; Safety; Vaccine; WHO

Indexed keywords

ADJUVANT; ALUMINUM; BCG VACCINE; CELL DNA; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; ISONIAZID; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; SMALLPOX VACCINE; SQUALENE; THIOMERSAL; VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

AUTISM; BELL PALSY; CHRONIC FATIGUE SYNDROME; DEVELOPING COUNTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FASCIITIS; GUILLAIN BARRE SYNDROME; HUMAN; INFECTION; INFECTION PREVENTION; LEUKEMIA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SUBACUTE SCLEROSING PANENCEPHALITIS; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 67049087153     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.40     Document Type: Review

References (94)

1. Institute of Medicine. Evidence concerning pertussis vaccines and other illnesses and conditions. In: Adverse Effects of Pertussis and Rubella Vaccines. Howson CP, Howe CJ, Fineberg HV (Eds). Institute of Medicine, Washington, DC, USA 144-186 (1991).
2. Oliveira MI, Curti SP, Figueiredo CA et al. Rash after measles vaccination: laboratory ana lysis of cases reported in Sao Paulo, Brazil. Rev. Saude Publica 36, 155-159 (2002). (Pubitemid 34746086)
3. Esteves K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull. World Health Organ. 66, 739-746 (1982).
4. Vogel FR, Hem SL. Immunologic adjuvants. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA (Eds). Elsevier, Philadelphia, PA, USA 69-79 (2004).
5. Finn TM, Egan W. Vaccine additives and manufacturing residuals in United States-licensed vaccines. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA (Eds). Elsevier, Philadelphia, PA, USA 81-90 (2004).
6. Ball R. Methods of ensuring vaccine safety. Expert Rev. Vaccines 1(2), 161-168 (2002). (Pubitemid 36686866)
7. WHO. Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations Agencies. WHO/IVB/05.19 (2005).
8. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55(RR-15), 1-48 (2006).
9. Pollard AJ. Childhood immunisation: what is the future? Arch. Dis. Child. 92, 426-433 (2007). (Pubitemid 46698141)
10. Menzies R, Turnour C, Chiu C, McIntyre P. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006. Commun. Dis. Intell. 32(Suppl.), S2-S67 (2008).
11. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56(RR-2), 1-24 (2007).
12. WHO. Influenza vaccines, position paper. Wkly Epidemiol. Rec. 80, 279-287 (2005).
13. Fiore AE, Shay DK, Haber P et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm. Rep. 56(RR-6), 1-54 (2007).
14. Breiman RF, Zanca JA. Of floors and ceilings: defining, assuring, and communicating vaccine safety. Am. J. Public Health 87(12), 1919-1920 (1997).
15. John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur. J. Epidemiol. 16, 601-606 (2000).
16. Bonah C, Menut P. La longue marche d'un vétéran. Recherche 356, 70-73 (2002).
17. Offit PA. The Cutter incident, 50 years later. N. Engl. J. Med. 352, 1411-1412 (2005). (Pubitemid 40471448)
18. The Epidemic that Never Was: Policy Making and the Swine Flu Scare. Neustadt RE, Fineberg HV (Eds). Vintage Books, New York, NY, USA (1983).
19. Centers for Disease Control and Prevention (CDC). Withdrawal of rotavirus vaccine recommendation. MMWR Morb. Mortal. Wkly Rep. 48, 1007 (1999).
20. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350, 896-903 (2004). (Pubitemid 38252537)
21. Chen RT. Vaccines risks: real, perceived and unknown. Vaccine 17, S41-S46 (1999). (Pubitemid 29516679)
22. Davies P, Chapman S, Leask J. Antivaccination activists on the world wide web. Arch. Dis. Child. 87, 22-25 (2002). (Pubitemid 34753767)
23. Nasir L. Reconnoitering the antivaccination web sites: news from the front. J. Fam. Pract. 49, 731-733 (2000).
24. Wolfe RM, Sharp LK, Lipsky MS. Content and design attributes of antivaccination web sites. JAMA 287, 3245-3248 (2002). (Pubitemid 34692578)
25. Wakefield AJ, Murch SH, Anthony A et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351, 637-641 (1998). (Pubitemid 28098447)
26. Burgess DC, Burgess MA, Leask J. The MMR vaccination and autism controversy in United Kingdom 1998-2005: inevitable community outrage or a failure of risk communication? Vaccine 24, 3921-3928 (2006).
27. Jansen VA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. Science 301, 804 (2003). (Pubitemid 36962614)
28. Murch SH, Anthony A, Casson DH et al. Retraction of an interpretation. Lancet 363, 750 (2004). (Pubitemid 38315163)
29. WHO. Hepatitis B immunization - WHO position. Wkly Epidemiol. Rec. 73, 329 (1998).
30. Hernán MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 63, 838-842 (2004). (Pubitemid 39297644)
31. Mikaeloff Y, Caridade G, Suissa S, Tardieu M. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 72, 873-880 (2009).
32. Clements CJ, Greenhough P, Shull D. How vaccine safety can become political - the example of polio in Nigeria. Curr. Drug Saf. 1, 117-119 (2006).
33. Iskander J, Pool V, Zhou W, English-Bullard R; The VAERS Team. Data mining in the US using the Vaccine Adverse Event Reporting System. Drug Saf. 29, 375-384 (2006). (Pubitemid 43752540)
34. Chen RT, Davis RL, Rhodes PH. Special methodological issues in pharmacoepidemiology studies of vaccine safety. In: Pharmacoepidemiology (4th Edition). Strom BL (Ed.). John Wiley & Sons, Sussex, UK 455-486 (2005).
35. Ståhl M, Edwards IR, Bowring G, Kiuru A, Lindquist M. Assessing the impact of drug safety signals from the WHO database presented in 'SIGNAL': results from a questionnaire of National Pharmacovigilance Centres. Drug Saf. 26, 721-727 (2003).
36. Yamey G. UK's yellow card scheme to be extended. BMJ 319, B1322 (1999).
37. Kelleher HC, Carmichael AE. Yellow card reporting. Br. J. Gen. Pract. 43(366), 35(1993). (Pubitemid 23050722)
38. Varricchio F, Iskander J, Destefano F et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr. Infect. Dis. J. 23, 287-294 (2004). (Pubitemid 38508877)
39. McMahon AW, Iskander JK, Haber P, Braun MM, Ball R. Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine. Vaccine 26(3), 427-429 (2008).
40. Lawrence G, Menzies R, Burgess M et al. Surveillance of adverse events following immunisation: Australia, 2000-2002. Commun. Dis. Intell. 27, 307-323 (2003).
41. Cortes-Fernandez G, Bastos Camacho LA, Carvalho MS. Surveillance system of vaccine adverse events and local data analysis - the experience in a middle-sized city in Brazil, 1999-2001. Vaccine 23, 2349-2353 (2005).
42. Linquist AM. Seeing and Observing in International Pharmacovigilance. World Health Organization Collaborating Centre for International Drug Monitoring, Uppsala, Sweden (2003).
43. Letourneau M, Wells G, Walop W, Duclos P. Improving global monitoring of vaccine safety: a quantitative analysis of adverse event reports in the WHO Adverse Reactions Database. Vaccine 26, 1185-1194 (2008).
44. Letourneau M, Wells G, Walop W, Duclos P. Improving global monitoring of vaccine safety: a survey of national centres participating in the WHO Programme for International Drug Monitoring. Drug Saf. 31, 389-398 (2008).
45. Global Advisory Committee on Vaccine Safety, 6-7 June 2006. Wkly Epidemiol. Rec. 81, 273-278 (2006).
46. Bonhoeffer J, Heininger U, Kohl K et al. Standardized case definitions of adverse events following immunization (AEFI). Vaccine 22, 547-550 (2004). (Pubitemid 38114879)
47. Kohl KS, Gidudu J, Bonhoeffer J et al. The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine 25, 5671-5674 (2007). (Pubitemid 47043207)
48. WHO, Western Pacific Regional Office. Immunization safety surveillance: guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. WPRO/EPI/99.01.
49. Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 22, 2064-2070 (2004). (Pubitemid 38581081)
50. Farrington CP, Nash J, Miller E. Case series ana lysis of adverse reactions to vaccines: a comparative evaluation. Am. J. Epidemiol. 143, 165-173 (1996). (Pubitemid 26158114)
51. Whitaker H. The self controlled case series method. BMJ 337, 1069 (2008).
52. Hviid A, Stellfeld M, Wolhlfahrt J, Melbye M. Association between thimerosal containing vaccines and autism. JAMA 290, 1763-1766 (2003). (Pubitemid 37430627)
53. Immunization Safety Review Committee. Immunization Safety Review: Vaccines and Autism. Institute of Medicine, Washington DC, USA (2004).
54. Haber P, Patel M, Izurieta HS et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 121, 1206-1212 (2008).
55. World Health Organization. Vaccine safety. Vaccine Safety Advisory Committee. Wkly Epidemiol. Rec. 74, 337-340 (1999).
56. Folb P, Bernatowska E, Chen RT et al. A global perspective on vaccine safety and public health: the global advisory committee on vaccine safety. Am. J. Public Health 94, 1926-1931 (2004). (Pubitemid 39434822)
57. Global Advisory Committee on Vaccine Safety, 16-17 December 2002. Wkly Epidemiol. Rec. 78, 17-20 (2003).
58. Global Advisory Committee on Vaccine Safety, 20-21 June 2002. Wkly Epidemiol. Rec. 77, 389-394 (2002).
59. Global Advisory Committee on Vaccine Safety, 11-12 June 2003. Wkly Epidemiol. Rec. 78, 282-284 (2003).
60. Hesseling AC, Rabie H, Marais BJ et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin. Infect. Dis. 42, 548-558 (2006). (Pubitemid 43202529)
61. Global Advisory Committee on Vaccine Safety, 29-30 November 2006. Wkly Epidemiol. Rec. 82, 18-24 (2007).
62. Meeting of the immunization Strategic Advisory Group of Experts, November 2006 - conclusions and recommendations. Wkly Epidemiol. Rec. 82, 1-16 (2007).
63. Global Advisory Committee on Vaccine Safety, 12-13 June 2007. Wkly Epidemiol. Rec. 82, 252-259 (2007).
64. Martinez-Mora M, Alvarez-Pasqui MJ, Rodriguez-Salvanes F. Vaccines and internet: characteristics of the Vaccine Safety Net web sites and suggested improvements. Vaccine 26, 6950-6955 (2008).
65. Henderson RH. Vaccinations in the health strategies of developing countries. Scand. J. Infect. Dis. Suppl. 76, 7-14 (1990).
66. Muraskin W. The Global Alliance for Vaccines and Immunization: is it a new model for effective public-private cooperation in international public health? Am. J. Public Health 94, 1922-1925 (2004). (Pubitemid 39434821)
67. Martin JF, Marshall J. New tendencies and strategies in international immunisation: GAVI and the Vaccine Fund. Vaccine 21, 587-592 (2003). (Pubitemid 36091964)
68. Rossi IA, Zuber PL, Dumolard L, Walker DG, Watt J. Introduction of Hib vaccine into national immunization programmes: a descriptive ana lysis of global trends. Vaccine 25, 7075-7080 (2007). (Pubitemid 47464682)
69. Costa A, Henao-Restrepo AM, Hall SM, Jarrett S, Hoekstra EJ. Determining measles-containing vaccine demand and supply: an imperative to support measles mortality reduction efforts. J. Infect. Dis. 187(Suppl. 1), S22-S28 (2003). (Pubitemid 36583928)
70. Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 26, 4978-4983 (2008).
71. Mahoney RT, Krattiger A, Clemens JD, Curtiss R 3rd. The introduction of new vaccines into developing countries. IV: global access strategies. Vaccine 25, 4003-4011 (2007). (Pubitemid 46616993)
72. Jadhav S, Datla M, Kreeftenberg H, Hendriks J. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine 26, 1611-1615 (2008).
73. Milstien JB, Kaddar M, Kieny MP. The impact of globalization on vaccine development and availability. Health Affairs 25(4), 1061-1069 (2006).
74. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 20, 109-117 (1999). (Pubitemid 29101275)
75. Chen RT, Glasser JW, Rhodes P et al. The Vaccine Safety Datalink Project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics 99, 765-773 (1997). (Pubitemid 27231345)
76. Black S. Global Vaccine Safety DataNet meeting. Expert Rev. Vaccines 7(1), 15-20 (2008).
77. Kimman TG, Vandebriel RJ, Hoebee B. Genetic variation in the response to vaccination. Comm. Genet. 10, 201-217 (2007). (Pubitemid 47482080)
78. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin. Pharmacol. Ther. 82, 653-664 (2007). (Pubitemid 350114830)
79. WHO and UNICEF joint reporting process www.who.int/immunization- monitoring/routine/joint-reporting/en/index.html (Accessed 9 April 2009)
80. The Uppsala Monitoring Center. The global intelligence network for benefits and risk in medicinal products www.who-umc.org (Accessed 9 April 2009)
81. IMPACT www.cps.ca/english/surveillance/impact/impact.htm (Accessed 9 April 2009)
82. Brighton Collaboration. Definition and guidelines www. brightoncollaboration.org/internet/en/index/definition-guidelines.html (Accessed 9 April 2009)
83. Clinical Immunization Safety Assessment (CISA) Network www.cdc.gov/vaccinesafety/cisa (Accessed 9 April 2009)
84. Global Advisory Committee on Vaccine Safety (GACVS) www.who.int/vaccine- safety (Accessed 9 April 2009)
85. Global Advisory Committee on Vaccine Safety. Topics www.who.int/vaccine- safety/topics/en/ (Accessed 9 April 2009)
86. Global Advisory Committee on Vaccine Safety: response to the paper (in press) by Y Mikaeloff and colleagues in Neurology entitled 'Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood', October 2008 www.who.int/vaccine-safety/topics/hepatitisb/multiple-sclerosis/oct-2008/en/ index.html (Accessed 9 April 2009)
87. Vaccine Safety Net www.who.int/immunization-safety/safety-quality/ vaccine-safety-websites/en/index.html (Accessed 9 April 2009)
88. WHO. State of the world vaccines and immunization - rev ed. Geneva 2003, World Health Organization www.who.int/vaccines-documents/docspdf04/wwwsowv-e.pdf (Accessed 9 April 2009)
89. GAVI Alliance. What you can apply for www.gavialliance.org/support/what/ index.php (Accessed 9 April 2009)
90. Vaccine regulation - further information. Strengthening national regulatory authorities (NRAs) www.who.int/immunization-standards/vaccine- regulation/nra-rp-info/en/index.html (Accessed 9 April 2009)
91. A system for the prequalification of vaccines for UN supply www.who.int/immunization-standards/vaccine-quality/pq-suppliers/en/index.html (Accessed 9 April 2009)
92. Council for International Organizations of Medical Sciences www.cioms.ch (Accessed 9 April 2009)
93. Vaccine pharmacovigilance definition. www.cioms.ch/finalvpvdef.pdf (Accessed 9 April 2009)
94. SANEVA www.paho-vb.org:8080/portal/esavi.do (Accessed 9 April 2009)